Results 21 to 30 of about 80,158 (218)
Conditionally Replicating Vectors Mobilize Chimeric Antigen Receptors against HIV
Molecular Therapy: Methods & Clinical Development, 2020 Human immunodeficiency virus (HIV) is an attractive target for chimeric antigen receptor (CAR) therapy. CAR T cells have proved remarkably potent in targeted killing of cancer cells, and we surmised that CAR T cells could prove useful in eradicating HIV ...
Ryan Z. Urak +8 more
doaj +1 more source
Chimeric Antigen Receptors Expand the Repertoire of Antigenic Macromolecules for Cellular Immunity
Cells, 2021 T-cell therapies have made significant improvements in cancer treatment over the last decade. One cellular therapy utilizing T-cells involves the use of a chimeric MHC-independent antigen-recognition receptor, typically referred to as a chimeric antigen ...
John T. Keane, Avery D. Posey
doaj +1 more source
Gene modification strategies for next-generation CAR T cells against solid cancers
Journal of Hematology & Oncology, 2020 Immunotherapies have become the backbone of cancer treatment. Among them, chimeric antigen receptor (CAR) T cells have demonstrated great success in the treatment of hematological malignancies.
Yonggui Tian +3 more
doaj +1 more source
Nature Communications, 2023 Chimeric antigen receptors (CARs) and synthetic Notch (synNotch) receptors are engineered cell-surface receptors that sense a target antigen and respond by activating T cell receptor signaling or a customized gene program, respectively.
Elisa Ruffo +10 more
doaj +1 more source
Frontiers in Immunology, 2019 Immune cell therapies based on the integration of synthetic antigen receptors comprise a powerful strategy for the treatment of diverse diseases, most notably T cells engineered to express chimeric antigen receptors (CAR) for targeted cancer therapy.
Theresa Pesch +9 more
doaj +1 more source
Comparison of lentiviral and sleeping beauty mediated αβ T cell receptor gene transfer.
PLoS ONE, 2013 Transfer of tumour antigen-specific receptors to T cells requires efficient delivery and integration of transgenes, and currently most clinical studies are using gamma retroviral or lentiviral systems.
Anne-Christine Field +9 more
doaj +1 more source
Cell Transplantation, 2022 Use of chimeric antigen receptors (CARs), as an immune cell therapy, has generated excellent clinical outcomes against hematologic tumors in recent years.
Xiaodi Zhang +7 more
doaj +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Claudin‐6 has emerged as a promising immunotherapeutic target, yet protein‐level data in atypical teratoid/rhabdoid tumors (AT/RTs) have been inconsistent. We analyzed 36 well‐characterized AT/RT samples and found membranous claudin‐6 protein expression in 58% of cases, with striking enrichment in the molecular subgroup AT/RT‐TYR (100%) and ...
Victoria E. Fincke +4 more
wiley +1 more source
Pediatric Blood &Cancer, EarlyView.ABSTRACT Immune effector cell‐associated hemophagocytic lymphohistiocytosis‐like syndrome (IEC‐HS) is a life‐threatening hyperinflammatory toxicity distinct from cytokine release syndrome (CRS) and neurotoxicity following chimeric antigen receptor T‐cell (CAR‐T) therapy. In a single‐institution retrospective cohort of pediatric and young adult patients
Thomas J. Galletta +6 more
wiley +1 more source
Huli yanjiu, 2020 Reviewing application progress on immunotherapy with chimeric antigen receptor T cell（CAR⁃T） in patients with hematological malignancies from 4 aspects,such as collection,pretreatment,note on cell reinfusion,and treatment complication of chimeric antigen
MENG Rui, XU Li, WAN Ying
doaj